Potent, selective 5-HT3 receptor antagonist with weak antagonistic action against other 5-HT3 receptors.
A selective serotonin receptor antagonist, that binds to 5-HT3 receptors on vagal nerve terminals and in the chemoreceptor trigger zone of the area postrema to block serotonin stimulation and subsequent vomiting after emetogenic stimuli.
Oral treatment has adequate biologic availability, comparable efficacy as with intravenous treatment.
Subcutaneous administration has similar bioavailability as does intravenous delivery and is a reasonable alternative route of administration.
Usage of doses greater than 1 mg not associated with improved efficacy.
Available as a slow subcutaneous injection over 20 to 30 seconds, with dexamethasone ((Sustol).